npj Breast Cancer (Sep 2021)

Association of APOE4 genotype and treatment with cognitive outcomes in breast cancer survivors over time

  • Kathleen Van Dyk,
  • Catherine M. Crespi,
  • Julienne E. Bower,
  • Judith E. Carroll,
  • Laura Petersen,
  • Patricia A. Ganz

DOI
https://doi.org/10.1038/s41523-021-00327-4
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 4

Abstract

Read online

Abstract This prospective longitudinal study of breast cancer survivors (n = 167) examined the association of apolipoprotein ε4 (APOE ε4) genotype with cognition and interactions with chemotherapy or endocrine therapy up to 6 years after treatment. In general, we found no effects of ε4 across timepoints and treatment exposures; post hoc analysis at 3–6 years suggested a trend towards worse cognition in the domains of attention and learning among ε4 carriers exposed to endocrine therapy. Further study is needed.